ID

30009

Beschreibung

To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone; ODM derived from: https://clinicaltrials.gov/show/NCT01070043

Link

https://clinicaltrials.gov/show/NCT01070043

Stichworte

  1. 04.05.18 04.05.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

4. Mai 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Hypertension NCT01070043

Eligibility Hypertension NCT01070043

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
participants over 18 years of age with hypertension defined as sitting systolic blood pressure between 140 mmhg and 180 mmhg or sitting diastolic blood pressure between 90 mmhg and 120 mmhg.
Beschreibung

Age | Hypertensive disease | Sitting systolic blood pressure | Sitting diastolic blood pressure

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0020538
UMLS CUI [3]
C1319893
UMLS CUI [4]
C1319894
high risk participants ( defined as having: (diabetes mellitus, chronic renal disease, framingham 10-year risk score >10%, established coronary artery disease (cad), or cad equivalents including carotid artery disease, peripheral arterial disease (pad), abdominal aortic aneurysm (aaa))with hypertension defined as sitting systolic blood pressure between 130 mmhg and 180 mmhg or sitting diastolic blood pressure between 80 mmhg and 120 mmhg.
Beschreibung

Study Subject High risk | Diabetes Mellitus | Chronic Kidney Diseases | Framingham coronary heart disease 10 year risk score | Coronary Artery Disease Established | Coronary Artery Disease Equivalent | Carotid Artery Diseases | Peripheral Arterial Diseases | Aortic Aneurysm, Abdominal | Hypertensive disease | Sitting systolic blood pressure | Sitting diastolic blood pressure

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0332167
UMLS CUI [2]
C0011849
UMLS CUI [3]
C1561643
UMLS CUI [4]
C1277687
UMLS CUI [5,1]
C1956346
UMLS CUI [5,2]
C0443211
UMLS CUI [6,1]
C1956346
UMLS CUI [6,2]
C0205163
UMLS CUI [7]
C0007273
UMLS CUI [8]
C1704436
UMLS CUI [9]
C0162871
UMLS CUI [10]
C0020538
UMLS CUI [11]
C1319893
UMLS CUI [12]
C1319894
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
known or suspected secondary hypertension
Beschreibung

Secondary hypertension | Secondary hypertension Suspected

Datentyp

boolean

Alias
UMLS CUI [1]
C0155616
UMLS CUI [2,1]
C0155616
UMLS CUI [2,2]
C0750491
known new york heart association (nyha) functional class iv heart failure
Beschreibung

Heart failure New York Heart Association Classification

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0018801
UMLS CUI [1,2]
C1275491
history of myocardial infarction, transient ischemic attack or cerebrovascular accident within the preceding 3 months
Beschreibung

Myocardial Infarction | Transient Ischemic Attack | Cerebrovascular accident

Datentyp

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0007787
UMLS CUI [3]
C0038454
clinically significant valvular disease
Beschreibung

Valvular disease

Datentyp

boolean

Alias
UMLS CUI [1]
C3258293
women who are pregnant, intend to become pregnant or are breastfeeding
Beschreibung

Pregnancy | Pregnancy, Planned | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0032992
UMLS CUI [3]
C0006147
participants who have severe medical condition(s) that in the view of the investigator prohibits participation in the study
Beschreibung

Medical condition Severe | Study Subject Participation Status Excluded

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C2348568
UMLS CUI [2,2]
C0332196
participants who have hypersensitivity to the investigational/ reference drug or any of the components in the formulation.
Beschreibung

Hypersensitivity Investigational New Drugs | Hypersensitivity Investigational New Drugs Component

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0013230
UMLS CUI [2,3]
C1705248
other protocol-defined inclusion/exclusion criteria may apply
Beschreibung

Eligibility Criteria Study Protocol

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563

Ähnliche Modelle

Eligibility Hypertension NCT01070043

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age | Hypertensive disease | Sitting systolic blood pressure | Sitting diastolic blood pressure
Item
participants over 18 years of age with hypertension defined as sitting systolic blood pressure between 140 mmhg and 180 mmhg or sitting diastolic blood pressure between 90 mmhg and 120 mmhg.
boolean
C0001779 (UMLS CUI [1])
C0020538 (UMLS CUI [2])
C1319893 (UMLS CUI [3])
C1319894 (UMLS CUI [4])
Study Subject High risk | Diabetes Mellitus | Chronic Kidney Diseases | Framingham coronary heart disease 10 year risk score | Coronary Artery Disease Established | Coronary Artery Disease Equivalent | Carotid Artery Diseases | Peripheral Arterial Diseases | Aortic Aneurysm, Abdominal | Hypertensive disease | Sitting systolic blood pressure | Sitting diastolic blood pressure
Item
high risk participants ( defined as having: (diabetes mellitus, chronic renal disease, framingham 10-year risk score >10%, established coronary artery disease (cad), or cad equivalents including carotid artery disease, peripheral arterial disease (pad), abdominal aortic aneurysm (aaa))with hypertension defined as sitting systolic blood pressure between 130 mmhg and 180 mmhg or sitting diastolic blood pressure between 80 mmhg and 120 mmhg.
boolean
C0681850 (UMLS CUI [1,1])
C0332167 (UMLS CUI [1,2])
C0011849 (UMLS CUI [2])
C1561643 (UMLS CUI [3])
C1277687 (UMLS CUI [4])
C1956346 (UMLS CUI [5,1])
C0443211 (UMLS CUI [5,2])
C1956346 (UMLS CUI [6,1])
C0205163 (UMLS CUI [6,2])
C0007273 (UMLS CUI [7])
C1704436 (UMLS CUI [8])
C0162871 (UMLS CUI [9])
C0020538 (UMLS CUI [10])
C1319893 (UMLS CUI [11])
C1319894 (UMLS CUI [12])
Item Group
C0680251 (UMLS CUI)
Secondary hypertension | Secondary hypertension Suspected
Item
known or suspected secondary hypertension
boolean
C0155616 (UMLS CUI [1])
C0155616 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Heart failure New York Heart Association Classification
Item
known new york heart association (nyha) functional class iv heart failure
boolean
C0018801 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Myocardial Infarction | Transient Ischemic Attack | Cerebrovascular accident
Item
history of myocardial infarction, transient ischemic attack or cerebrovascular accident within the preceding 3 months
boolean
C0027051 (UMLS CUI [1])
C0007787 (UMLS CUI [2])
C0038454 (UMLS CUI [3])
Valvular disease
Item
clinically significant valvular disease
boolean
C3258293 (UMLS CUI [1])
Pregnancy | Pregnancy, Planned | Breast Feeding
Item
women who are pregnant, intend to become pregnant or are breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0032992 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
Medical condition Severe | Study Subject Participation Status Excluded
Item
participants who have severe medical condition(s) that in the view of the investigator prohibits participation in the study
boolean
C3843040 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C2348568 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
Hypersensitivity Investigational New Drugs | Hypersensitivity Investigational New Drugs Component
Item
participants who have hypersensitivity to the investigational/ reference drug or any of the components in the formulation.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video